Basel-based CGC Genomics has raised €1.7 million in pre-Seed funding to innovate the interpretation of most cancers genome knowledge with its GenAI platform Qnomx, bringing to market their regulatory-grade generative AI answer for medical determination assist in oncology.
Backers embody Heal Capital, Becker Ventures, Springboard Well being Angels, Superangels, and higher ventures – represented by enterprise angels Christoph Behn, Nicolas Weber, and Helmut Deschauer.
“With Qnomx, we’re constructing regulatory-compliant GenAI – enabling extra exact therapies with much less burden on medical professionals,” says James Creeden, MD PhD, Co-CEO of CGC Genomics and former Chief Medical Officer at Roche & Basis Drugs.
Based in 2023 by Dr Joerg Hoelzing, Dr James Creeden, MD PhD, and Marcus Olivecrona, CGC Genomics specialise within the regulated software of generative AI in oncology. Its platform Qnomx is growing the “world’s first regulatory-grade GenAI answer for deciphering most cancers genome knowledge” – with the objective of constructing extra exact therapies quicker and extra extensively obtainable.
CGC Genomics goals to launch Qnomx as the primary generative AI answer in most cancers diagnostics with regulatory approval – compliant with IVDR, MDR, and the European AI Act. The platform is being developed underneath an ISO 13485-certified high quality administration system and presents a clear, auditable various to unregulated instruments like ChatGPT, that are at the moment being utilized in some medical settings.
“With Qnomx, we’re supporting visionary founders constructing the AI infrastructure for the way forward for precision medication. Qnomx impresses with an skilled crew and a groundbreaking strategy to one of many area’s core challenges: making genomic knowledge really actionable. We’re assured they may set a brand new customary for the secure use of generative AI in medical diagnostics and remedy,” says Christian Lautner, Founding Managing Companion of Heal Capital.
Most cancers circumstances are rising globally – in accordance with knowledge supplied to EU-Startups, in 2022 alone, over 20 million new circumstances have been identified. Focused remedy more and more depends on molecular tumor evaluation utilizing Subsequent Technology Sequencing (NGS). Nonetheless, solely 20–30% of sufferers who ought to obtain sequencing in accordance with medical tips really bear such evaluation. The primary cause: round 80% of oncologists report that immediately’s NGS studies are too complicated to shortly and confidently make therapy selections. Deciphering them requires specialised information and is time-consuming – a major barrier in every day medical apply.
That is the place Qnomx seems to come back in. The AI-powered platform processes the outcomes of NGS evaluation (i.e., the ultimate report from tertiary evaluation), interprets them into clear, clinically related summaries – reportedly saving time, lowering prices, and minimising interpretation errors.
“We’re excited to announce our collaboration with CGC Genomics. As one in all Bavaria’s main laboratory medication corporations, with over 650 workers throughout 12 places, we’re dedicated to steady innovation to offer our healthcare companions with top-tier diagnostics and streamlined processes. Based mostly on our experience in molecular pathology and genetic testing, we see vital potential in CGC Genomics’ Qnomx platform to additional optimize the interpretation of complicated genomic knowledge.
“This partnership permits us to extend the effectivity and high quality of our NGS course of and make a priceless contribution to precision medication. We’re assured this collaboration will advance diagnostics and stay up for the subsequent steps with CGC Genomics,” says Marc Becker, Managing Director of Labor Becker MVZ eGbR.
Inside use of the software has proven vital effectivity beneficial properties, now being validated in pilot tasks with Labor Becker and the OnkoMedeor Group. As a substitute of as much as two hours of guide evaluation, Qnomx claims to ship a concise medical abstract of key findings in minutes – within the native language and at all times with a “human within the loop.”
“Diagnostics can scale – interpretation can’t. That’s precisely what we’re altering with Qnomx,” explains Dr Joerg Hoelzing, Co-CEO of CGC Genomics.
“Synthetic intelligence will essentially rework healthcare – however solely whether it is regulated, explainable, and responsibly utilized. That’s precisely what CGC Genomics delivers: a crew with deep medical experience, a transparent imaginative and prescient, and a product that’s secure for sufferers, scalable, and economically viable. Qnomx democratises entry to precision most cancers remedy – bringing cutting-edge medication to the place experience is at the moment missing,” says Tina Dreimann, Founder and managing director of higher ventures.
